Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy
- 212 Downloads
Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID gastropathy continues to be a particular concern in many patients, especially those at increased risk for serious adverse events, including the elderly. Complicating the diagnosis of NSAID gastropathy is its silent course, which, up to half of the time, is asymptomatic. Several strategies are currently employed by physicians to mitigate the risk of serious gastrointestinal events. These include either addition of a proton pump inhibitor to current nonselective NSAID therapy or the use of a cyclo-oxygenase-2—selective NSAID. Although these agents are effective at mitigating the overall risk of gastrointestinal adverse events, they fail to address NSAID-related cardiovascular and renal risks. Due to their reduced systemic absorption, topical NSAIDs may present a viable option for patients at increased risk for serious NSAID-related adverse events, including gastropathy.
KeywordsCelecoxib Peptic Ulcer Disease Esomeprazole Gastrointestinal Adverse Event Boxed Warning
Technical editorial and medical writing assistance for the preparation of this manuscript was provided by Lauren Burawski, MA, Synchrony Medical LLC, West Chester, PA, USA. Funding for this support was provided by Mallinckrodt Inc., a Covidien company, Hazelwood, MO, USA.
Dr Roth is a current stakeholder in Transdel Pharmaceuticals and serves as a consultant and speaker for Covidien.
- 1.Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. We started it — can we stop it?. Arch Intern Med 1986 Jun; 146 (6): 1075–6Google Scholar
- 2.Lanas A, Garcia-Tell G, Armada B, et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk of cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 2011 Apr 14; 9: 38Google Scholar
- 5.US FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Medical product safety information. COX-2 selective and non-selective non-steroidal anti-inflammatory drugs NSAIDs [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151410.htm [Accessed 2012 Feb 24]
- 11.Richette P, Hilliquin P, Bertin P, et al. Comparison of general practitioners and rheumatologists’ prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 2011 Apr; 12: 72Google Scholar
- 19.Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247–55Google Scholar
- 23.Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145–55Google Scholar
- 26.American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty), 2008 [online]. Available from URL: http://www.aaos.org/research/guidelines/OAKguideline.pdf [Accessed 2011 Jul 26]
- 27.National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59. London: NICE, 2008Google Scholar
- 33.Pavlicevic I, Kuzmanic M, Rumboldt M, et al. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 2008 Fall; 15 (3): e372-82Google Scholar
- 34.McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. Plos Med 2011 Sep; 8 (9): e1001098Google Scholar
- 35.Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011 Jan 11; 342: c7086Google Scholar
- 42.Duexis® (ibuprofen and famotidine) [package insert]. Hunt Valley (MD): Pharmaceutics International, Inc., 2011Google Scholar
- 43.Weinblatt ME, Genovese MC, Klivitz AJ, et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials [abstract]. Arthritis Rheum 2010; 62 Suppl. 10: 945Google Scholar
- 44.Voltaren® gel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2009Google Scholar
- 45.PENNSAID® (diclofenac sodium topical solution) 1.5% w/w [package insert]. Hazelwood (MO): Mallinckrodt Inc., 2010 JunGoogle Scholar